Your browser doesn't support javascript.
loading
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Fasching, Peter A; Hein, Alexander; Kolberg, Hans-Christian; Häberle, Lothar; Uhrig, Sabrina; Rübner, Matthias; Belleville, Erik; Hack, Carolin C; Fehm, Tanja N; Janni, Wolfang; Hartmann, Arndt; Erber, Ramona; Theuser, Anna-Katharin; Brucker, Sara Y; Hartkopf, Andreas D; Untch, Michael.
Affiliation
  • Fasching PA; Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany. Electronic address: peter.fasching@fau.de.
  • Hein A; Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
  • Kolberg HC; Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
  • Häberle L; Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany; Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Germany.
  • Uhrig S; Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
  • Rübner M; Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
  • Belleville E; ClinSol GmbH & Co KG, Würzburg, Germany.
  • Hack CC; Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
  • Fehm TN; Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Germany.
  • Janni W; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
  • Hartmann A; Erlangen University Hospital, Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
  • Erber R; Erlangen University Hospital, Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
  • Theuser AK; Institut für Frauengesundheit GmbH, Erlangen, Germany.
  • Brucker SY; Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany.
  • Hartkopf AD; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
  • Untch M; Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Germany.
Eur J Cancer ; 184: 1-9, 2023 05.
Article in En | MEDLINE | ID: mdl-36871424
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Triple Negative Breast Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Triple Negative Breast Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Country of publication: